NEW YORK, Feb. 23, 2015 /PRNewswire/ -- Abbott Diagnostics' IVD business grew nearly seven percent last year by concentrating on its core lab portfolio. The company remains the world's #2 in vitro diagnostic company, according to Kalorama Information. The healthcare market research firm says Abbott demonstrated improved sales in immunoassays and clinical chemistry. Kalorama provided market share of the top three IVD companies in its report Abbott Diagnostics: Company Profile.
The report can be obtained at: http://www.kaloramainformation.com/Abbott-Diagnostics-Company-8693175/.
The Illinois-based company said its Core Laboratory Diagnostics sales increased 6.9 percent to $3.8 billion in 2014 on an operational basis, driven by strong growth in the U.S. and internationally as a result of competitive wins and double-digit growth in emerging markets. In new products, Abbott received U.S. FDA clearance for the first automated galectin-3 test for use on its ARCHITECT platform to aid doctors in assessing the prognosis of people diagnosed with chronic heart failure. Also in September, preliminary results from a clinical study sponsored by the British Heart Foundation suggested that Abbott's ARCHITECT High Sensitive Troponin test, currently available outside the United States, may help improve the diagnosis and prognosis of patients presenting with symptoms of a heart attack. Abbott said that their data showed the test could be particularly beneficial for women, who are often under-diagnosed.
Strongest growth came from the United States, the result of several large health system customers selecting Abbott's integrated and flexible solutions to manage large testing volumes and increase operational efficiencies.
Abbott's core lab products include: ABBOTT PRISMnEXT, an automated immunoassay analyzer designed to perform chemiluminescent immunoassay (ChLIA) technology; the ARCHITECT family of instruments run chemistries and immunoassays for cancer, infectious disease, cardiovascular and thyroid disease, fertility and pregnancy. Abbott has reported that more than 10,000 Architect systems are used worldwide.
Kalorama's report looks at the top three IVD companies and Abbott's place among them, and provides 2013 segment-level IVD revenue estimates for the company. Abbott Diagnostics: Company Profile can be obtained at: http://www.kaloramainformation.com/Abbott-Diagnostics-Company-8693175/
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com
Logo - http://photos.prnewswire.com/prnh/20140801/132634
SOURCE Kalorama Information
Share this article